Friday, 19 Jul 2019

You are here

Nonadherence is Costly for Patients in Pain

A comparative cohort study of patients with osteoarthritis (OA), gout, diabetic peripheral neuropathy (pDPN), post-herpetic neuralgia (PHN), and fibromyalgia (FM) shows that nonadherence to pain medications is high and leads to greater overall health care resource utilization and costs. 

Data was collected from a retrospective cohort study that used claims (MarketScan Commercial and Medicare Databases) between 2006-2013, identifying newly diagnosed with OA, GT, pDPN, PHN, or FM and identifed patients as either adherent, nonadherent, or "unsure" according to published pain management guidelines using a claims-based algorithm. 

The cohorts included patients with OA (n=441,465), gout (n=76,361), pDPN (n=10,645), PHN (n=4,010), and FM (n=150,321). Adherence to pain treatement guidelines was seen in:

  • 51.1% of OA
  • 25% of Gout
  • 59.5% of pDPN
  • 54.9% of PHN
  • 33.5% of FM

Those who were adherent had significantly (P < 0.05) fewer emergency department (ED) visits and lower proportions with hospitalizations or ED visits.

Adherent patients had significantly lower mean health care costs. Comparison of health care costs between adherent and nonadherent patients showed the following significant increases (all P < 0.001) in adjusted costs pre-index to postindex:

  • OA: $5,286 vs $9,532
  • Gout: $3,631 vs $7,873
  • pDPN: $9,578 vs $16,337
  • PHN: $2,975 vs $5,146
  • FM $2,911 vs $3,708

Pain medication nonadherence leads to significantly higher health care resource utilization and costs, suggesting a substantial need for education and other interventions that can lower this gap and its consequences.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Rituximab Superior to Cyclosporine for Membranous Nephropathy

The NEJM has reported that rituximab (RTX) and cyclosporine (CYA) was noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and was superior in maintaining proteinuria remission up to 24 months. 

Management of Hemophagocytic Lymphohistiocytosis (HLH) in Adults

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome induced by activated macrophages and cytotoxic T cells.  HLH manifests recurrent fever, cytopenia, liver dysfunction, and a sepsis-like syndrome that may complicated by multiple organ failure.

More Trouble for Mallinckrodt’s Acthar Gel

Reuters has reported that Mallinckrodt Plc has tentatively agreed to pay $15.4 million to resolve a US Justice Department investigation into company promotional practices for Acthar gel.

FDA Public Review of CBD Oil

The US Food and Drug Administration convened a public hearing and specialty panel on May 31st to review the potential use, safety and effectiveness of cannabidiol (CBD) products that do not contain THC.

In his opening remarks, the FDA acting Commissioner Dr. Ned Sharpless said, "critical questions remain about the safety" of CBD products, especially since the growth of the CBD market has exploded in the past year.

Steroids, Not Biologics, Drive Arthroplasty Infections in RA

Medicare and Truven MarketScan administrative data study (2006 through 2015) of rheumatoid arthritis (RA) undergoing arthroplasty found that while that the risks of perioperative infection was similar across biologics, the infection risk with glucocorticoid use, especially at > 10 mg/d, was significantly greater.